These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33112010)

  • 1. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
    Garbayo-Salmons P; Expósito-Serrano V
    Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
    Sánchez J; Alvarez L; Cardona R
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(4):364-366. PubMed ID: 36314621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(5):364-366. PubMed ID: 36314703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
    Koski R; Kennedy KK
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study.
    Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C
    J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data.
    Unsel M
    Asian Pac J Allergy Immunol; 2024 Jun; 42(2):138-146. PubMed ID: 33638629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of UAS7 among children with chronic spontaneous urticaria.
    Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072
    [No Abstract]   [Full Text] [Related]  

  • 15. "Omalizumab plus": Combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: A multicenter UK series.
    Rutkowski K; Wagner A; Jui-Lin Choo K; Smith H; Savic S; Grattan CE
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1400-1401.e2. PubMed ID: 33181342
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose omalizumab use in patients with chronic spontaneous urticaria.
    Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293
    [No Abstract]   [Full Text] [Related]  

  • 17. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
    Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
    Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
    [No Abstract]   [Full Text] [Related]  

  • 18. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896
    [No Abstract]   [Full Text] [Related]  

  • 19. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254
    [No Abstract]   [Full Text] [Related]  

  • 20. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
    Abe N; Bohgaki M; Kasahara H
    Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.